Pamir Ozan 4

What Happened

• Pamir Ozan, Chief Financial Officer of Niagen Bioscience, received a grant of 62,131 derivative shares on 2026-02-19. The filing reports an acquisition price/value of $0 (derivative instrument), and the award is subject to vesting rather than an open-market purchase or immediate sale.

Key Details

• Transaction date: 2026-02-19; Form 4 filed: 2026-02-24 (filed 5 days after the transaction — outside the typical 2-business-day window, so the filing appears late).
• Amount granted: 62,131 shares (derivative security) at $0 reported.
• Vesting: One-fourth of the shares vest on each anniversary of the grant date (4-year annual vesting — see footnote).
• Shares owned after the transaction: not specified in the filing.
• No sale or cashless exercise occurred — this was a grant/award, not a disposition.

Context

• This appears to be an equity award (commonly RSUs or similar) that vests over time; such grants are routine for executive compensation and do not by themselves indicate a buy/sell signal. Because the award is subject to multi-year vesting, its value to the insider depends on future employment and company stock performance.